Rechercher des projets européens

25 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet

 34

 TERMINÉ 

EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases. In addition, of the 600 new cases of ES o ...
Voir le projet

 21

 TERMINÉ 

Mutanome Engineered RNA Immuno-Therapy (MERIT)

Date du début: 1 juin 2013, Date de fin: 30 nov. 2017,

The Mutanome Engineered RNA Immuno-Therapy (MERIT) project aims to clinically translate and industrially validate a pioneering RNA-based immunotherapy approach to target the individual tumour antigen signature. MERIT focuses on previous inventions, fits into the overall business and innovation needs of the partners, and addresses triple-negative breast cancer patients with high medical need. The M ...
Voir le projet

 5

 TERMINÉ 

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE (ARTFORCE)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2017,

Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by:1. Optimizing local control by introducing novel radiation techniques resulting ...
Voir le projet

 14

 TERMINÉ 

Biomaterials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway (BIOtrachea)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

Age-related cancers, especially of the trachea, are neoplastic lesions that significantly impact upon the lives of thousands of European patients each year. Unfortunately, most present with inoperable lesions for which median survival is less than 12 months. Based on our previous clinically successful experiences with in vivo completely tissue engineered tracheal replacement in benign tracheal dis ...
Voir le projet

 13

 TERMINÉ 

Rational molecular Assessments and Innovative Drug Selection (RAIDS)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Cervical cancer (CC) is the second most common cause of cancer deaths in women worldwide. The main objective of the RAIDs project is to use this model system which is accessible to repeat biopsies to learn how to stratify patients into targeted therapies. The patients’ tumors will be classified into molecular subtypes based on their molecular profile by use of high-throughput technologies (sequen ...
Voir le projet

 19

 TERMINÉ 

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies (PanCareSurFup)

Date du début: 1 févr. 2011, Date de fin: 31 janv. 2017,

Over the last 40 years, treatment for childhood and adolescent cancer has improved greatly; 5- year survival after childhood cancer is now 80% in developed countries. Approximately 1 individual in 750 of young adults is now a childhood cancer survivor. Epidemiologic data on the number of European childhood cancer long-term survivors are not available, but estimates suggest a number between 300,000 ...
Voir le projet

 18

 TERMINÉ 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet

 29

 TERMINÉ 

European Clinical trials in Rare Sarcomas within an integrated translational trial network (EUROSARC)

Date du début: 1 déc. 2011, Date de fin: 30 nov. 2016,

Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given sarcoma rarity as a group, but even more as individual entities, few prospective clinical ...
Voir le projet

 22

 TERMINÉ 

Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients (CTCtrap)

Date du début: 1 sept. 2012, Date de fin: 31 août 2016,

"Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treat ...
Voir le projet

 12

 TERMINÉ 

European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults (ENS@T-CANCER)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,

Among patients with adrenal masses Adrenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH) are found with a low incidence but very unfavorable prognosis. Due to this poor clinical outcome, concomitant hormone dysregulation and limited treatment options the two cancer entities severely impact on affected patients. However, the rarity of the tumors also impedes clinical studies which ar ...
Voir le projet

 17

 TERMINÉ 

EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS (ENCCA)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

"ENCCA aims to establish a durable, European Virtual Institute clinical and translational research in childhood and adolescent cancers that will define and implement an integrated research strategy and will facilitate the necessary investigator-driven clinical trials to introduce the new generation of biologically targeted drugs into standard of care for children and adolescents with cancer. This ...
Voir le projet

 34

 TERMINÉ 

Genetic epidemiological investigation into the association between endometriosis and cutaneous melanoma (MELENDO2)

Date du début: 1 août 2012, Date de fin: 28 déc. 2015,

Earlier work, including that led by the fellow during her PhD, suggests a higher melanoma risk in women with endometriosis, a prevalent and potentially debilitating disease with unknown aetiology. A genetic link has been speculated as pigmentary traits consistently associated with melanoma were also found to be associated with endometriosis risk. The present project will expand upon this intriguin ...
Voir le projet

 1

 TERMINÉ 

Non-Invasive Optical Biopsy for Cancer Assessment using ultra high resolution Full-Field Optical Coherence Tomography (CAReIOCA)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2015,

Along the cancer care workflow, existing preoperative and intraoperative procedures such as the identification of small tumourous areas or the precise resection of tumors show significant fail rates, due to the inability of current imaging techniques to perform a reliable in situ diagnosis. Moreover the complete pathological diagnosis, often based on histology slides preparation, is usually only a ...
Voir le projet

 5

 TERMINÉ 

STRENGTHENING COOPERATION IN MOLECULAR BIOMEDICINE BETWEEN EU AND UKRAINE (COMBIOM)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2015,

True European leadership at the emerging frontiers of biomedical sciences could be achieved more effectively with participation of the most prominent scientists from the ENP countries. Ukraine is a country of high potential for scientific and technological development. Institute of Molecular Biology and Genetics is one of the leading scientific centres in molecular biomedicine area in Ukraine, whi ...
Voir le projet

 3

 TERMINÉ 

Cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation (PROCARDIO)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2015,

Epidemiological evidence has established a link between cardiovascular disease and exposure of the heart and major vessels to doses above 500mGy. At lower doses the evidence for a detrimental effect is inconclusive. In part, this is due to the lack of appropriate epidemiological studies, coupled with lack of knowledge of the processes involved that is needed for construction of mathematical models ...
Voir le projet

 15

 TERMINÉ 

Cognitive and Cerebrovascular Effects Induced by Low Dose Ionising Radiation (CEREBRAD)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2015,

The major elements of scientific uncertainty in the context of radiation protection policy and of risk assessment for cerebrovascular diseases, set the following key topics (1) the direct assessment of health effects through epidemiological studies of groups exposed to low doses, (2) doses-response and biological effects from different types of radiation and (3) the biological processes in cells a ...
Voir le projet

 12

 TERMINÉ 

WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients (WINTHER)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2015,

Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patientsCurrent medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, ...
Voir le projet

 12

 TERMINÉ 

Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer (RESPONSIFY)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2015,

Individualisation of cancer therapy based on standardized biomarker assays is one of the most demanding challenges in cancer medicine. In the RESPONSIFY consortium, we will integrate information on response prediction from different breast cancer types and methodologies into biomarker tests for targeted therapies in the clinical routine setting. Those tests will be developed for commercialisation ...
Voir le projet

 14

 TERMINÉ 

Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics (PREDICT)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,

"The strategic development of accurate biomarkers to predict response to therapy in cancer medicine will enhance clinical outcome and reduce the health economic impact of drug resistant disease. The PREDICT consortium will identify and validate predictive biomarkers for two drugs which have direct anti-tumour cell and anti-angiogenic activity and for which no established predictive biomarkers of t ...
Voir le projet

 16

 TERMINÉ 

Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis (CURELUNG)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2014,

"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understan ...
Voir le projet

 11

 TERMINÉ 

Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies (INFLA-CARE)

Date du début: 1 janv. 2009, Date de fin: 30 juin 2013,

Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cells in the initiation, progression and metastasis of malignancy. The objective of the collaborative integrated project INFLA-CARE is to structure a European collective of scientific and technological excellence in the field of ‘Inflammation & Cancer’ which will ...
Voir le projet

 22

 TERMINÉ 

Integrated Micro-Nano-Opto Fluidic systems for high-content diagnosis and studies of rare cancer cells (CAMINEMS)

Date du début: 1 juil. 2009, Date de fin: 31 déc. 2012,

The project aims at developing a new integrated and automated microfluidic tool for cancer cells screening. This instrument will have a reliability and power much beyond state of the art (capture yield increased by a factor from 10X to 100X and multimodal typing of the cells in 3D high resolution images), allowing earlier and more accurate diagnosis, prognosis and selection of treatments of cancer ...
Voir le projet

 9

 TERMINÉ 

Oral Off-patent Oncology Drugs for Kids (03K)

Date du début: 1 sept. 2008, Date de fin: 31 août 2011,

"There is an urgent need for appropriate oral formulations of anticancer drugs for the treatment of paediatric malignancies in children. The goal of the O3K consortium is to develop oral liquid formulations of Cyclophosphamide and Temozolomide, important chemotherapeutics which have been identified in the list of paediatric needs by EMEA (EMEA/197972/2007). Both off-patent drugs are widely used or ...
Voir le projet

 9

 TERMINÉ 

Prospective cohort studies of children with substantial medical diagnostic exposure (CHILD-MED-RAD)

Date du début: 1 sept. 2008, Date de fin: 30 nov. 2009,

The growing use of diagnostic X-rays and of high-dose techniques (CT, interventions) in children and adolescents is a topic of concern in radiological protection. Studies of other populations indicate that children are generally more sensitive to health effects of radiation than adults. In addition, children have a longer life-span to express any radiation-related health effect and, because of the ...
Voir le projet

 10